EMCDDA Case study 5 — Expanding HCV screening and hepatitis treatment and care for PWID to harm reduction centres

C. Devaux, V. Arendt

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The aim of this project was to expand screening and treatment for HCV among PWID in Luxembourg. An intervention research project was implemented at three harm reduction sites and at the national supervised drug consumption facility in the city of Luxembourg, offering HCV, human immunodeficiency virus (HIV), hepatitis B virus (HBV) and syphilis serologies and viral load, liver biomarkers, and a transient elastography (non‐invasive assessment of liver stiffness) for people currently injecting drugs. To accelerate access to treatment and limit HCV transmission among this key risk group, the provision of direct‐acting antiviral treatment and virological follow‐up for PWID with HCV infection was subsequently initiated at the harm reduction centres and the national drug consumption facility. The study demonstrated the feasibility of offering comprehensive HCV care at these low‐threshold agencies for PWID, including proactive screening for a wider range of infectious diseases among this population.
Original languageEnglish
Title of host publicationHepatitis C: new models of care for drugs services
PublisherEMCDDA
Pages43-49
Number of pages7
Publication statusPublished - Jul 2019

Fingerprint

Dive into the research topics of 'EMCDDA Case study 5 — Expanding HCV screening and hepatitis treatment and care for PWID to harm reduction centres'. Together they form a unique fingerprint.

Cite this